文献速递糖尿病肥胖与代谢综合征

GLP-1受体激动剂的抗炎作用

Anti-inflammatory effects of GLP1-RA drugs.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述了GLP-1受体激动剂(GLP-1RA)在多种器官系统中的直接抗炎效应,汇总了临床前模型和临床试验的证据。GLP-1RA通过同时靶向代谢和炎症通路,可能提供心血管代谢与免疫调节的双重保护,但因果关系、精确分子机制及向非代谢性炎症疾病的转化程度尚待明确。

要点

  • GLP-1RA除降糖减重外,还具有跨器官的直接抗炎作用。
  • 慢性炎症驱动糖尿病、心血管病、神经退行性疾病和炎症性肠病等。
  • GLP-1RA可能兼具心血管代谢和免疫调节双重保护作用。

核心结论

  • GLP-1RA通过靶向代谢和炎症通路,可能提供心血管代谢与免疫调节的双重保护。
  • GLP-1RA的抗炎效应在多种疾病中展现治疗潜力,但因果关系和分子机制尚待阐明。

研究设计与样本

  • 本文为综述,汇总了临床前模型和临床试验中GLP-1RA抗炎效应的证据。

主要发现

  • 积累的证据表明GLP-1RA在多个器官系统中发挥直接抗炎作用。
  • 慢性炎症是糖尿病、心血管疾病、神经退行性疾病和炎症性肠病等常见疾病的驱动因素。

临床怎么用

  • GLP-1RA可作为同时改善代谢和炎症的潜在治疗选择,适用于2型糖尿病和肥胖患者。
  • 对非代谢性炎症疾病的应用需进一步研究验证。

局限性

  • 抗炎效应的因果关系尚未明确。
  • 精确分子机制未完全阐明。
  • 抗炎效应转化为非代谢性炎症疾病有效治疗的程度不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are established treatment options for type 2 diabetes and obesity. This class of medications has redefined care by lowering glucose, reducing body weight, and improving cardiovascular outcomes. Beyond metabolic benefits, accumulating evidence indicates that GLP-1RA exert direct anti-inflammatory effects across multiple organ systems. Chronic inflammation is a driving force behind many prevalent diseases, including diabetes, cardiovascular disease, neurodegenerative disorders, and inflammatory bowel disease. This review summarizes the current evidence of the anti-inflammatory effects of GLP-1RA, highlighting data from preclinical models and clinical trials across different diseases. By targeting both metabolic and inflammatory pathways, GLP-1RA may offer dual cardiometabolic and immunomodulatory protection, positioning these agents as promising candidates for broader therapeutic applications. However, several key questions remain regarding causality, the precise molecular mechanisms involved, and the extent to which these anti-inflammatory effects can be translated into effective therapies for nonmetabolic inflammatory diseases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Quintana L, Tabaza N, Kurt B, et al. Anti-inflammatory effects of GLP1-RA drugs. J Clin Endocrinol Metab. 2026. PMID: 42219869. doi:10.1210/clinem/dgag218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。